Antitumor effects of dual inhibition of the Src and insulin-like growth factor-1 receptor (IGF-1R) pathways in prostate cancer (PCa). Safety and efficacy of ketoconazole (K) in patients (pts) with ...
What happens to men with prostate cancer whose PSA starts to rise while on neo-adjuvant androgen ablation therapy prior to external radiation? No significant financial relationships to disclose. This ...
PSADT is vital for monitoring prostate cancer recurrence and guiding treatment decisions, yet often inaccurately calculated by physicians. Inconsistent PSADT documentation can lead to treatment delays ...
Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...
The natural history of biochemical recurrence (BCR) managed with delayed hormonal therapy is well documented by data from Johns Hopkins. However, as many patients receive treatment prior to metastasis ...
Standardized PSADT calculations are crucial for timely prostate cancer treatment, potentially preventing metastasis and reducing treatment costs. Casdatifan shows promise in clear cell RCC, with a 100 ...
Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study ...
PSA doubling time less than three months in men with PSA progression after RP raised risk 20-fold. PSA doubling time (PSADT), Gleason score, and time to PSA progression are strong independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results